Long-term follow-up for 39 newly diagnosed diffused large B-cell lymphoma patients treated by (R)-EPOCH / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 333-338, 2014.
Artigo
em Chinês
| WPRIM (Pacífico Ocidental)
| ID: wpr-349712
Biblioteca responsável:
WPRO
ABSTRACT
The purpose of this study was to evaluate the efficacy and safety of (R)-EPOCH protocol on patients with diffuse large B-cell lymphoma(DLBCL). From February 2004 to April 2009, a total of 39 patients who suffered from DLBCL and received (R)-EPOCH protocol were enrolled in the study. The median age of patients was 52 years old. 24 patients were on stage I/II, and 15 cases were on stage III/IV. Patients with stage I/II were administered with 4-6 cycles of (R)-EPOCH, while other patients with stage III/IV received 6-8 cycles of (R)-EPOCH. DLBCL patients with bulky disease received radiotherapy after completion of chemotherapy. 39 patients received a total of 209 cycles of chemotherapy and the median chemotherapy cycles was 6 (range, 2-8 cycles). The results showed that the overall response rate of 39 assessable patients was 87.2%, including 28 patients (71.8%) in complete remission (CR) and 6 patients (15.4%) in partial remission(PR). With a median follow-up of 57.7 months, the 1-year overall survival rate was 81.8%, while 70.9% for 3-year and 58.8% for 5-year. The major toxicity of (R)-EPOCH protocol was hematologic toxicity and the incidence of grade III-IV neutropenia and anemia were 29.2% and 14.4%, respectively. Other toxicities were mild, no treatment-related deaths occurred. At the end of follow-up,no secondary tumors occurred. It is concluded that (R)-EPOCH protocol is a effective and safe protocol for the patients with DLBCL.
Texto completo:
Disponível
Contexto em Saúde:
ODS3 - Meta 3.4 Reduzir as mortes prematuras devido doenças não transmissíveis
Problema de saúde:
Linfomas e Mieloma Múltiplo
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Vincristina
/
Prednisona
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Doxorrubicina
/
Seguimentos
/
Linfoma Difuso de Grandes Células B
/
Ciclofosfamida
/
Usos Terapêuticos
/
Tratamento Farmacológico
/
Etoposídeo
Tipo de estudo:
Estudo diagnóstico
/
Guia de prática clínica
/
Estudo observacional
/
Estudo prognóstico
Limite:
Adolescente
/
Adulto
/
Idoso
/
Idoso, 80 anos ou mais
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Journal of Experimental Hematology
Ano de publicação:
2014
Tipo de documento:
Artigo